Expertise in
1
conditions

Joris C. Arts

AZ Sint Lucas Brugge
Brugge, VLG, BE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
AZ Sint Lucas Brugge
Brugge, VLG, BE 

Overview

Joris Arts practices practicing medicine in Brugge, Belgium.

Mr. Arts is highly rated in 1 condition, according to our data. His clinical expertise encompasses Indigestion, Osteomyelitis, Irritable Bowel Syndrome (IBS), Diarrhea, and Bone Graft.

He is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

AZ Sint Lucas Brugge
Brugge, VLG, Belgium
Other Locations
Leuven, VLG, Belgium
Koersel, VLG, Belgium
AZ Delta
Roeselare, VLG, Belgium
Genk, VLG, Belgium
Liege, WAL, Belgium
Beerse, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Peripheral Histamine 1 Receptor Blockade in IBS
Peripheral Histamine 1 Receptor Blockade in IBS
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: Ebastine
Study Phase: Phase 4
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.
REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.
Enrollment Status: Unknown
Publish Date: July 31, 2020
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
View 4 Less Clinical Trials

66 Total Publications

Spatial distribution and structural discrimination of quorum sensing metabolites in Pseudomonas aeruginosa by MALDI-MSI.
Spatial distribution and structural discrimination of quorum sensing metabolites in Pseudomonas aeruginosa by MALDI-MSI.
Journal: The Analyst
Published: July 27, 2026

Frequently Asked Questions about Joris C. Arts

Is Joris C. Arts a top-rated expert for Indigestion?

MediFind is an objective health platform that identifies experts based on real-world data. Joris C. Arts is classified as an Advanced expert for Indigestion, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Joris C. Arts participate in research or clinical trials?

Yes. Joris C. Arts has published 66 articles and abstracts on conditions like Indigestion. You can view a list of Joris C. Arts's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Arts's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile